139 related articles for article (PubMed ID: 38124788)
1. Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With
Kim J; Lee Y
JTO Clin Res Rep; 2023 Dec; 4(12):100600. PubMed ID: 38124788
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
[No Abstract] [Full Text] [Related]
4.
Sentana-Lledo D; Academia E; Viray H; Rangachari D; Kobayashi SS; VanderLaan PA; Costa DB
Transl Lung Cancer Res; 2023 Jul; 12(7):1590-1610. PubMed ID: 37577308
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on Mobocertinib (TAK-788) in NSCLC with
Zhang SS; Zhu VW
Lung Cancer (Auckl); 2021; 12():61-65. PubMed ID: 34285620
[TBL] [Abstract][Full Text] [Related]
6. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
7. Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.
Chen X; Zha W; Su M; Meng N; Cao S; Niu B; Qi X
Front Pharmacol; 2023; 14():1053805. PubMed ID: 36817153
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
9. Advanced lung adenocarcinoma patient with
Jia K; Yang S; Chen B; Yu J; Wu Y; Li W; Zhou F; Wu F; Feng G; Ren S
Ann Transl Med; 2022 Mar; 10(6):386. PubMed ID: 35433998
[TBL] [Abstract][Full Text] [Related]
10. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
12. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
Watanabe N; Horio Y; Fujiwara Y
Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
[TBL] [Abstract][Full Text] [Related]
14. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
David GM; Maria Del Pilar BC; Cristina MR
J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
[TBL] [Abstract][Full Text] [Related]
15. Mobocertinib (TAK-788): A Targeted Inhibitor of
Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
[TBL] [Abstract][Full Text] [Related]
16. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
[TBL] [Abstract][Full Text] [Related]
17. Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines.
Olivier T; Prasad V
Transl Oncol; 2022 Sep; 23():101475. PubMed ID: 35785671
[TBL] [Abstract][Full Text] [Related]
18. Severe Psychiatric Symptoms in a Patient With
Kamel J; Meeder N; Cuellar S; Chan D; Huber M; Pasquinelli M; Hulbert A; Khaddour K; Feldman L
JTO Clin Res Rep; 2021 Nov; 2(11):100241. PubMed ID: 34766066
[TBL] [Abstract][Full Text] [Related]
19. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Shah V; McNatty A; Simpson L; Ofori H; Raheem F
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
[TBL] [Abstract][Full Text] [Related]
20. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]